Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model

被引:29
作者
Jesmin, S
Hattori, Y [1 ]
Sakuma, I
Mowa, CN
Kitabatake, A
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Pharmacol, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Cardiovasc Med, Sapporo, Hokkaido 0608638, Japan
[3] Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2002年 / 283卷 / 04期
关键词
vascular endothelial growth factor; hypoxia-inducible factor-1 alpha; advanced glycation end products; coronary capillary remodeling; angiotensin II; non-insulin-dependent diabetes mellitus;
D O I
10.1152/ajpheart.00299.2002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With the use of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of human non-insulin-dependent diabetes mellitus (NIDDM), we assessed whether ANG II is involved in coronary capillary angiogenesis at the insulin-resistant stage of NIDDM (20 wk of age). In OLETF rats, ANG II labeling and angiotensin type 1 (AT(1)) receptor expression in coronary vessels were increased more than in nondiabetic controls. A marked increase in vascular expression of vascular endothelial growth factor (VEGF) at both mRNA and protein levels was found in OLETF rats. The increased expression level of VEGF was associated with accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) activated by increased advanced glycation end products (AGEs). Morphometric analysis showed a significantly increased total coronary capillary density, which was a result of arterialization of the venular capillary portion in OLETF rats. Treatment of OLETF rats with candesartan, an AT(1) receptor blocker, inhibited vascular expressions of VEGF, HIF-1alpha, and AGEs, and ameliorated the morphometric changes. These results suggest a key role of ANG II in the pathogenesis of the coronary capillary remodeling in this NIDDM model.
引用
收藏
页码:H1387 / H1397
页数:11
相关论文
共 47 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]  
BATRA S, 1992, JPN HEART J, V33, P817
[3]  
Border WA, 1996, DIABETES METAB REV, V12, P309
[4]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[5]   EFFECTS OF LOSARTAN ON ANGIOTENSIN AND BRADYKININ PEPTIDES AND ANGIOTENSIN-CONVERTING ENZYME [J].
CAMPBELL, DJ ;
KLADIS, A ;
VALENTIJN, AJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (02) :233-240
[6]   Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action [J].
Cao, ZM ;
Hulthén, UL ;
Allen, TJ ;
Cooper, ME .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :793-799
[7]   Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states - A possible explanation for impaired collateral formation in cardiac tissue [J].
Chou, E ;
Suzuma, I ;
Way, KJ ;
Opland, D ;
Clermont, AC ;
Naruse, K ;
Suzuma, K ;
Bowling, NL ;
Vlahos, CJ ;
Aiello, LP ;
King, GL .
CIRCULATION, 2002, 105 (03) :373-379
[8]   Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells [J].
Chua, CC ;
Hamdy, RC ;
Chua, BHL .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1998, 1401 (02) :187-194
[9]  
FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141
[10]   Role of vascular endothelial growth factor in regulation of physiological angiogenesis [J].
Ferrara, N .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 280 (06) :C1358-C1366